184 related articles for article (PubMed ID: 26130461)
1. Evaluation of Epigenetic Drug Targeting of Heterogenous Tumor Cell Fractions Using Potential Biomarkers of Response in Ovarian Cancer.
Singh AK; Chandra N; Bapat SA
Clin Cancer Res; 2015 Nov; 21(22):5151-63. PubMed ID: 26130461
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic regulation of IQGAP2 promotes ovarian cancer progression via activating Wnt/β-catenin signaling.
Deng Z; Wang L; Hou H; Zhou J; Li X
Int J Oncol; 2016 Jan; 48(1):153-60. PubMed ID: 26549344
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
Zhong S; Fields CR; Su N; Pan YX; Robertson KD
Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
[TBL] [Abstract][Full Text] [Related]
5. Integrative prediction of gene function and platinum-free survival from genomic and epigenetic features in ovarian cancer.
Wrzeszczynski KO; Varadan V; Kamalakaran S; Levine DA; Dimitrova N; Lucito R
Methods Mol Biol; 2013; 1049():35-51. PubMed ID: 23913207
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.
Heller G; Schmidt WM; Ziegler B; Holzer S; Müllauer L; Bilban M; Zielinski CC; Drach J; Zöchbauer-Müller S
Cancer Res; 2008 Jan; 68(1):44-54. PubMed ID: 18172295
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic inhibition of epigenetic modification reveals targets of aberrant promoter methylation in Ewing sarcoma.
Nestheide S; Bridge JA; Barnes M; Frayer R; Sumegi J
Pediatr Blood Cancer; 2013 Sep; 60(9):1437-46. PubMed ID: 23508900
[TBL] [Abstract][Full Text] [Related]
8. Identification of candidate methylation-responsive genes in ovarian cancer.
Menendez L; Walker D; Matyunina LV; Dickerson EB; Bowen NJ; Polavarapu N; Benigno BB; McDonald JF
Mol Cancer; 2007 Jan; 6():10. PubMed ID: 17254359
[TBL] [Abstract][Full Text] [Related]
9. The potential of DNA modifications as biomarkers and therapeutic targets in oncology.
Jankowska AM; Millward CL; Caldwell CW
Expert Rev Mol Diagn; 2015; 15(10):1325-37. PubMed ID: 26394702
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells.
Zhang C; Li H; Zhou G; Zhang Q; Zhang T; Li J; Zhang J; Hou J; Liew CT; Yin D
J Pathol; 2007 Jun; 212(2):134-42. PubMed ID: 17471463
[TBL] [Abstract][Full Text] [Related]
12. Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers.
Gloss BS; Patterson KI; Barton CA; Gonzalez M; Scurry JP; Hacker NF; Sutherland RL; O'Brien PM; Clark SJ
Cancer Lett; 2012 May; 318(1):76-85. PubMed ID: 22155104
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma.
Foltz G; Ryu GY; Yoon JG; Nelson T; Fahey J; Frakes A; Lee H; Field L; Zander K; Sibenaller Z; Ryken TC; Vibhakar R; Hood L; Madan A
Cancer Res; 2006 Jul; 66(13):6665-74. PubMed ID: 16818640
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic inactivation of the tumor suppressor gene RIZ1 in hepatocellular carcinoma involves both DNA methylation and histone modifications.
Zhang C; Li H; Wang Y; Liu W; Zhang Q; Zhang T; Zhang X; Han B; Zhou G
J Hepatol; 2010 Nov; 53(5):889-95. PubMed ID: 20675009
[TBL] [Abstract][Full Text] [Related]
15. TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells.
Cardenas H; Vieth E; Lee J; Segar M; Liu Y; Nephew KP; Matei D
Epigenetics; 2014 Nov; 9(11):1461-72. PubMed ID: 25470663
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic Therapies in Ovarian Cancer Alter Repetitive Element Expression in a
McDonald JI; Diab N; Arthofer E; Hadley M; Kanholm T; Rentia U; Gomez S; Yu A; Grundy EE; Cox O; Topper MJ; Xing X; Strissel PL; Strick R; Wang T; Baylin SB; Chiappinelli KB
Cancer Res; 2021 Oct; 81(20):5176-5189. PubMed ID: 34433584
[TBL] [Abstract][Full Text] [Related]
17. Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells.
Liu Z; Marquez M; Nilsson S; Holmberg AR
Oncol Rep; 2008 Jul; 20(1):151-4. PubMed ID: 18575731
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic biomarkers in epithelial ovarian cancer.
Gloss BS; Samimi G
Cancer Lett; 2014 Jan; 342(2):257-63. PubMed ID: 22245949
[TBL] [Abstract][Full Text] [Related]
19. Gene silencing of MIR22 in acute lymphoblastic leukaemia involves histone modifications independent of promoter DNA methylation.
Li X; Liu J; Zhou R; Huang S; Huang S; Chen XM
Br J Haematol; 2010 Jan; 148(1):69-79. PubMed ID: 19807731
[TBL] [Abstract][Full Text] [Related]
20. Epigenetics in ovarian cancer.
Seeber LM; van Diest PJ
Methods Mol Biol; 2012; 863():253-69. PubMed ID: 22359298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
